Overview
Clinical-stage company developing psilocybin-based treatments for obsessive-compulsive disorder, eating disorders, and other hard-to-treat psychiatric conditions. They focus on indication-specific treatment protocols backed by rigorous clinical evidence.
More in Psychedelics
Latest industry news
NIH-Backed Device Gives People With Paralysis a New Path to Communication
2026-10-14 · Research
ABILITY Neurotech Begins Clinical Testing of Its Brain-Computer Interface System
2026-10-13 · Research
Flourish Emerges From Stealth With Bezos and Google Ventures Backing to Decode the Nervous System
2026-10-12 · Funding
Cala Health Launches Next-Generation TAPS Therapy Wearable Nationwide for Tremor and Parkinson's Patients
2026-10-11 · Product
Company details
Category
🍄 Psychedelics
Location
New York, NY, USA
Funding
Series A · $15M
Website
ceruvialifesciences.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →